首页> 外文期刊>The Journal of Physiology >Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy.
【24h】

Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy.

机译:他汀类肌病钝化的Akt / FOXO信号传导和控制萎缩和加油的基因激活。

获取原文
获取原文并翻译 | 示例
           

摘要

Statins are used clinically for cholesterol reduction, but statin therapy is associated with myopathic changes through a poorly defined mechanism. We used an in vivo model of statin myopathy to determine whether statins up-regulate genes associated with proteasomal- and lysosomal-mediated proteolysis and whether PDK gene expression is simultaneously up-regulated leading to the impairment of muscle carbohydrate oxidation. Animals were dosed daily with 80 mg kg(-1) day(-1) simvastatin for 4 (n = 6) and 12 days (n = 5), 88 mg kg(-1) day(-1) simvastatin for 12 days (n = 4), or vehicle (0.5% w/v hydroxypropyl-methylcellulose and 0.1% w/v polysorbate 80; Control, n = 6) for 12 days by oral gavage. We found, in biceps femoris muscle, decreased Akt(Ser473), FOXO1(Ser253) and FOXO3a(Ser253) phosphorylation in the cytosol (P < 0.05, P < 0.05, P < 0.001, respectively) and decreased phosphorylation of FOXO1 in the nucleus after 12 days simvastatin when compared to Control (P < 0.05). This was paralleled by a marked increase in the transcription of downstream targets of FOXO, i.e. MAFbx (P < 0.001), MuRF-1 (P < 0.001), cathepsin-L (P < 0.05), PDK2 (P < 0.05) and PDK4 (P < 0.05). These changes were accompanied by increased PPARalpha (P < 0.05), TNFalpha (P < 0.01), IL6 (P < 0.01), Mt1A (P < 0.01) mRNA and increased muscle glycogen (P < 0.05) compared to Control. RhoA activity decreased after 4 days simvastatin (P < 0.05); however, activity was no different from Control after 12 days. Simvastatin down-regulated PI3k/Akt signalling, independently of RhoA, and up-regulated FOXO transcription factors and downstream gene targets known to be implicated in proteasomal- and lysosomal-mediated muscle proteolysis, carbohydrate oxidation, oxidative stress and inflammation in an in vivo model of statin-induced myopathy. These changes occurred in the main before evidence of extensive myopathy or a decline in the muscle protein to DNA ratio.
机译:他汀类药物在临床上可用于降低胆固醇,但他汀类药物疗法通过定义不明确的机制与肌病性改变有关。我们使用他汀类药物肌病的体内模型来确定他汀类药物是否上调与蛋白酶体和溶酶体介导的蛋白水解有关的基因,以及PDK基因表达是否同时上调导致肌肉糖类氧化受损。每天给动物服用80 mg kg(-1)天(-1)辛伐他汀4天(n = 6)和12天(n = 5),88 mg kg(-1)天(-1)辛伐他汀12天(n = 4)或溶媒(0.5%w / v羟丙基-甲基纤维素和0.1%w / v聚山梨酯80;对照组,n = 6)口服灌胃12天。我们发现,在股二头肌中,胞浆中的Akt(Ser473),FOXO1(Ser253)和FOXO3a(Ser253)磷酸化降低(分别为P <0.05,P <0.05,P <0.001),并且核中FOXO1的磷酸化降低与对照组相比,辛伐他汀治疗12天后(P <0.05)。同时,FOXO下游靶标,即MAFbx(P <0.001),MuRF-1(P <0.001),组织蛋白酶-L(P <0.05),PDK2(P <0.05)和PDK4的转录水平显着增加(P <0.05)。与对照组相比,这些变化伴随着PPARalpha(P <0.05),TNFalpha(P <0.01),IL6(P <0.01),Mt1A(P <0.01)mRNA的增加和肌肉糖原的增加(P <0.05)。辛伐他汀治疗4天后RhoA活性下降(P <0.05);但是,活动在12天后与对照组无差异。辛伐他汀独立于RhoA下调PI3k / Akt信号传导,并上调FOXO转录因子和下游基因靶标,已知与体内模型中的蛋白酶体和溶酶体介导的肌肉蛋白水解,碳水化合物氧化,氧化应激和炎症有关他汀类药物引起的肌病。这些变化主要发生在广泛肌病或肌肉蛋白质与DNA比率下降的证据之前。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号